A retrospective, observational study assessing clinical impact of drug interaction in the use of antipsychotics by HCV patients treated with pangenotypic direct-acting antivirals
Latest Information Update: 28 Dec 2022
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary) ; Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Most Recent Events
- 08 Nov 2022 Results of sub-analysis assessing the presence and severity of drug interactions in patients using antipsychotics and treated with Pangenotypic Direct-Acting Antivirals, presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases
- 24 Aug 2022 New trial record
- 26 Jun 2022 Results presented at The International Liver Congress 2022